We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Formaldehyde Substitute Fixatives Appraised for Histology

By LabMedica International staff writers
Posted on 28 Sep 2011
In histology and pathology laboratories, neutral buffered formalin (NBF) has been the gold standard fixative for decades, but formaldehyde is known to be toxic. More...


Other less toxic alcohol-based cross-linking or non–cross-linking fixatives have advantages that include faster fixation; elimination of carcinogenic vapors; better preservation of glycogen, DNA, and RNA; greater staining avidity; and no need for enzyme predigestion for immunohistochemical analysis.

Scientists at the University Medical Center Utrecht (the Netherlands) tested three cross-linking and non–cross-linking alcohol-based fixatives for routine staining in comparison with NBF, an aqueous solution of 4% buffered formaldehyde. The aim was to observe the fixation on tissue morphologic features and the quality of special histological stains and immunohistochemical stains in comparison with NBF.

Fresh tissue samples from many different organs were divided into four equal pieces and fixed in all fixatives for varying times. After paraffin embedding, staining with hematoxylin and eosin (H&E), seven common histochemical stains, and nine common immunohistochemical stains were performed. Fixation with the non-linking RCL2 (Alphelys; Plaisir, France) resulted in soft and slippery tissue, causing sectioning difficulties. The cross-linking the aldehyde-containing F-Solv (Adamas; Rhenen, The Netherlands) and the non–cross-linking FineFIX (Milestone; Bergamo, Italy) led to partial tissue disintegration during fixation.

F-Solv performed morphologically similar to NBF but needed considerable protocol adjustments before being applicable in daily histology and immunohistochemical practice. FineFIX did not necessitate major protocol changes but caused shrinkage artifacts, degranulation, and lysis of red blood cells (RBC). RCL2 generated morphologically overall good results without major protocol changes, but caused pigment deposition, degranulation, and erythrocytic lysis. The alcohol-based fixatives had positive and negative attributes and environmental drawbacks, and none was overall comparable to NBF with regard to macroscopy, morphologic evaluation, and immunohistochemical studies.

The authors concluded that before replacing formalin with another fixative in a surgical pathology laboratory, all levels of pathology must be examined thoroughly. At the histochemical and the immunohistochemical levels using the usual NBF-based protocols, NBF performance was superior, followed by FineFIX/RCL2 and F-Solv. The study was published online in for the October 2011 edition of the Journal of Clinical Pathology.

Related Links:

University Medical Center Utrecht
Alphelys
Adamas




Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
Rapid Sepsis Test
SeptiCyte RAPID
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.